Zimbabwe approves long-acting HIV prevention injection | The Herald (Top Stories) Sunday Mail Reporter ZIMBABWE has approved ...

African kingdom has accepted 15 men as part of a third-country deportation program. This program, which has been strongly ...

But the rollout is now being wielded as a political tool. What that “America First” slogan actually means for global health ...

Lenacapavir is a twice-yearly injectable drug produced by Gilead Sciences that is aimed at preventing HIV infection. In 2024, ...

Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...

About 1,000 doses of Gilead Sciences Inc's drug lenacapavir were delivered to Zambia and Eswatini last Thursday, U.S. and ...

The drug lenacapavir will be distributed to Eswatini and Zambia — the first step toward providing at least 2 million doses to the countries with the highest HIV burden, largely in Africa, by 2028.

Oct 30 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for its new prevention drug Yeztugo, ...

(Reuters) -Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for its new prevention drug Yeztugo, helping to boost its profit.

Pricing issues have taken precedence as CVS Health’s (NYSE:CVS) pharmacy benefit manager, CVS Caremark, continues to hold off adding Yeztugo, Gilead Sciences’ (NASDAQ:GILD) new HIV prevention drug, to ...

(Reuters) -The UK's drugs cost-effectiveness watchdog has given a positive recommendation for ViiV Healthcare's HIV drug, enabling access to the preventive medicine via the state health system in ...

Nigeria has secured a landmark agreement to drastically cut the cost of a revolutionary HIV prevention drug, lenacapavir, paving the way for millions of citizens to access the life-saving medicine and ...